HEMATOLOGY

Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.

AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.

Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.

A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.

Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.

Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Results from the phase 1b EQUATE study were favorable enough to initiate a phase 3 study, which will test itolizumab for the frontline treatment of acute graft-versus-host disease..

The FDA is no longer conducting a speedy review of the supplemental biologics license application for luspatercept-aamt as treatment for anemia in adults with non-transfusion-dependent beta thalassemia.

Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.

Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.

During a Targeted Oncology case-based roundtable discussion, Javier Pinilla-Ibarz, MD, PhD, discusses risk factors and prophylactic options for tumor lysis syndrome.

During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.

Orphan drug designation has been granted to HT-KIT from the FDA for the treatment of mastocytosis

The phase 3 EQUATOR clinical trial has been initiated in the United States for the treatment of patients with acute graft-versus-host disease.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

John Mascarenhas, MD, provides advice to oncologists on the use of pacritinib to treatment patients with myelofibrosis and severe thrombocytopenia.

In an interview with Targeted Oncology, Ronald Paquette, MD, discussed MDS and what factors may impact the success of a patient’s treatment when undergoing transplant.

John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.

The supplemental new drug application for ibrutinib as a potential treatment for pediatric chronic graft-versus-host disease is supported with findings from the phase 1/2 IMAGINE study.

The treatment and preventive agent landscape for graft-versus-host disease is growing for patients with hematologic malignancies who receive a stem cell transplant.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

SWOG 1318 results are promising for extended blinatumomab use in patients with acute lymphoblastic leukemia.

During a Targeted Oncology case-based roundtable event, Uday R. Popat, MD, discussed the approaches to identifying and managing graft-vs-host disease.

Ronald S. Go, MD, explains how toxicities of treatment for histiocytic neoplasms compared with toxicities observed in other malignancies.

Early evidence indicates that iterative detection, profiling, and targeting of minimal residual disease could improve outcomes and even lead to a cure.

An application for approval of a new dosing schedule of Rylaze has been submitted to the FDA.

With a partial clinical hold placed by the FDA, all studies of magrolimab plus azacitidine must halt screening and enrollment.

For the treatment of patients with myelodysplastic syndrome, the FDA has granted an orphan drug designation to eltanexor.

A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.